- Strong Dollar Plays Global Stability Role: Geithner
- Gold Hits $1,121, Barrick Chief Says Selloff Possible
- Wall Street Pay Is Often too High: Bill Gates
- Morgan Stanley Gets Aggressive in Luring Brokers
- Foreclosures Fall Again But Improvement Likely Fleeting
- Highest State Foreclosure Rates
- Jobless, Wal-Mart to Drive Sentiment on Thursday
- Yuan Critics Want Obama to Keep Campaign Promise
- Pricier Beer Helps AB InBev Operating Profit
- What to Expect From Disney Earnings?
- HP's Shot Across Cisco's Bow
- USC Football Blog Leads All-Access Space
- Clowning Around At Work
- Ahead of Earnings Disney Restructures Studio
- Nov. 11: Unusual Volume Leaders
- 3 'Clear Sailing' Mid-Caps For Investors: Strategist
- Intimate Apparel Sales Heating Up: Maidenform CEO
- A Day On The USS Harry S. Truman
- Global recovery seen risked by higher oil prices
- Syngenta acquires 2 seed companies in California
- Peugeot Citroen raises 2009 forecasts
- Brazil economy to grow 9 pct in 4Q, official says
- Salzgitter in Q3 loss of euro67 million
- Repsol Q3 profits down by nearly half
- Warming drives off Cape Cod's namesake, other fish
- Estonia's economic output down by 15.3 pct in Q3
- Ida further slows harvest for Southern farmers
Text Size 
NEW YORK - Shares of Cytokinetics Inc. plunged Thursday after the biotechnology company said development of a potential heart failure drug could take a year longer than previously anticipated.
The stock slid 76 cents, or 17.8 percent, to $3.51 in afternoon trading. Shares have traded between $1.38 and $5.55 over the last 52 weeks.
Late Wednesday, the company said it agreed with partner Amgen Inc. on conducting additional mid-to-late-stage studies on omecamtiv mecarbil for heart failure and renal dysfunction patients in 2011.
Lazard Capital Markets analyst Joel Sendek reaffirmed a "Buy" rating on Cytokinetics, but said the delayed timeline could affect milestone payments to Cytokinetics.
Cytokinetics also said its third-quarter loss narrowed on more revenue from collaborations.
The company recorded a loss of $8.2 million, or 14 cents per share, compared with a loss of $16.3 million, or 33 cents per share, during the same period a year prior. Revenue rose 76 percent to $5.5 million from $3.1 million.
Analysts polled by Thomson Reuters expected a loss of 22 cents per share on revenue of $2.9 million.
Print
Email
- Bernard and Ruth Madoff's personal possessions will be auctioned this weekend. Click ahead to see.
- US real estate prices have fallen dramatically, but some places are still doing well. See the best-performing zip codes this year.
- An Italian cashmere maker aims to make profits while creating ideal conditions for his workers.
- Just in time for the holidays, the Triumph company of Japan offers the latest innovation in women’s undergarments.
- The real result of health care reform will be bloated government and higher deficits, says Larry Kudlow.
- Vote and suggest your own, and remember--there's a fine line between a hero and a zero.
Data is a real-time snapshot *Data is delayed at least 15 minutes